Free Trial
NASDAQ:CUE

Cue Biopharma (CUE) Stock Price, News & Analysis

Cue Biopharma logo
$0.81 -0.03 (-3.11%)
As of 02:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Cue Biopharma Stock (NASDAQ:CUE)

Key Stats

Today's Range
$0.79
$0.86
50-Day Range
$0.58
$0.91
52-Week Range
$0.45
$1.99
Volume
113,076 shs
Average Volume
269,198 shs
Market Capitalization
$61.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

Cue Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

CUE MarketRank™: 

Cue Biopharma scored higher than 77% of companies evaluated by MarketBeat, and ranked 436th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cue Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cue Biopharma has received no research coverage in the past 90 days.

  • Read more about Cue Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Cue Biopharma are expected to grow in the coming year, from ($0.76) to ($0.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cue Biopharma is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cue Biopharma is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cue Biopharma has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Cue Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    1.47% of the outstanding shares of Cue Biopharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Cue Biopharma has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cue Biopharma has recently decreased by 4.31%, indicating that investor sentiment is improving.
  • Dividend Yield

    Cue Biopharma does not currently pay a dividend.

  • Dividend Growth

    Cue Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.47% of the outstanding shares of Cue Biopharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Cue Biopharma has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cue Biopharma has recently decreased by 4.31%, indicating that investor sentiment is improving.
  • Search Interest

    Only 1 people have searched for CUE on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cue Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.26% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 35.04% of the stock of Cue Biopharma is held by institutions.

  • Read more about Cue Biopharma's insider trading history.
Receive CUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CUE Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

CUE Stock Analysis - Frequently Asked Questions

Cue Biopharma's stock was trading at $1.09 at the beginning of 2025. Since then, CUE shares have decreased by 24.1% and is now trading at $0.8270.

Cue Biopharma, Inc. (NASDAQ:CUE) issued its quarterly earnings data on Monday, May, 12th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.03. The company earned $0.42 million during the quarter, compared to analysts' expectations of $0.90 million. Cue Biopharma had a negative net margin of 507.87% and a negative trailing twelve-month return on equity of 228.43%.

Cue Biopharma's top institutional investors include GC Wealth Management RIA LLC (4.42%) and Angeles Wealth Management LLC (0.16%). Insiders that own company stock include Daniel R Passeri, Anish Suri and Peter A Kiener.
View institutional ownership trends
.

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

Last Earnings
5/12/2025
Today
8/06/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CUE
CIK
1645460
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$4.00
Low Price Target
$4.00
Potential Upside/Downside
+377.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$40.67 million
Net Margins
-507.87%
Pretax Margin
-507.87%
Return on Equity
-228.43%
Return on Assets
-114.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.03
Quick Ratio
1.03

Sales & Book Value

Annual Sales
$9.29 million
Price / Sales
6.80
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.28 per share
Price / Book
2.99

Miscellaneous

Outstanding Shares
75,350,000
Free Float
66,112,000
Market Cap
$63.15 million
Optionable
Optionable
Beta
1.53

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CUE) was last updated on 8/6/2025 by MarketBeat.com Staff
From Our Partners